Erlotinib and Docetaxel in Second Line of Treatment in Patients With Non Small Cell Lung Cancer

NCT01350817 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

156

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: Erlotinib + docetaxel
DRUG: Docetaxel

Sponsor

University Hospital, Limoges

Collaborators

[object Object]